The OJC Episode 39 with Bishal Gyawali: Chewing the ASCO 2021 Fat

The Oncology Journal Club Podcast Episode 39

In today’s special ASCO 2021 episode Eva Segelov and Hans Prenen chew the ASCO 2021 fat with Bishal Gyawali.  It’s a thorough and entertaining discussion covering practice changing developments, global oncology, drug approval processes and controversial trials.

We hope you enjoy listening… drop us a line on Twitter with any comments.

This week’s papers:

1. Mileshkin, L. et al Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). J Clin Oncol 39, 2021 (suppl 15; abstr LBA3). DOI: 10.1200/JCO.2021.39.15_suppl.LBA3. Access online here.

2. Xu, R-H, et al. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). J Clin Oncol 39, 2021 (suppl 15; abstr LBA2). DOI: 10.1200/JCO.2021.39.15_suppl.LBA2. Access online here.

3. Morris, M.J., et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol 39, 2021 (suppl 15; abstr LBA4). DOI: 10.1200/JCO.2021.39.15_suppl.LBA4. Access online here.

4. Raimondi, L., et al. Usefulness of assessment of circulating tumor DNA(ctDNA) of cerebrospinal fluid(CSF) samples for early detection of brain metastasis (BrM) in patients with triple-negative breast cancer (TNBC). DOI: 10.1200/JCO.2021.39.15_suppl.507 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 507-507. Published online May 28, 2021. Access online here.
5. Kunz, P. Looking Under the Surface: Exposing the Iceberg of Sexual Harassment. Discussion available online here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen

Associate Professor Bishal Gyawali

Bishal Gyawali

Dr Gyawali is a medical oncologist with work experience in various low- and high- income countries. He graduated medical school in Nepal with seven gold medals and received his PhD from Nagoya University, Japan as a MEXT scholar. He then practiced as a medical oncologist at Civil Service Hospital, Kathmandu, Nepal. He currently works as a medical oncologist and scientist in the Division of Cancer Care and Epidemiology at the Queen’s University Cancer Research Institute in Kingston, Ontario, Canada, where he is also an Assistant Professor of Public Health Sciences.

He also serves as a medical consultant for the not-for-profit Anticancer Fund, Belgium, and as editorial board member for the Journal of Global Oncology and ecancer. His clinical and research interests include cancer policy, global oncology, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, and supportive care. Dr. Gyawali is an advocate of the “cancer groundshot,”  a term he coined to imply that research investment should be made on known high-value interventions in cancer care that are affordable and easy to implement globally. Dr. Gyawali is active in the oncology and clinical research communities on Twitter: @oncology_bg

Rachael Babin

Connect with us on Twitter @OncologyNewsAus